Kiyatec Inc.’s Post

Targeting #HLA peptides is and stays a valid approach that can lead to therapies with clinical impact: First ever #TCR #Tcell #immunotherapy and second TCR-based therapy (after the T cell engager Kimmtrak) approved for the treatment of #synovialsarcoma! Great news for #cancer patients and for the TCR field in general. At Alithea Bio , we are profiling #HLA peptides in never seen precision and sensitivity and with our HLA-Compass, we have unprecedented knowledge of HLA peptide presentation in health and disease. #precisionmedicine #cellandgenetherapy #act

Great news! Another targeted therapy approved for patients with early-stage/locally advanced NSCLC after surgical resection 🫁 How do we “select” the patients who will derive benefit? 🧪This highlights the important role of biomarker testing to #personalize therapy even in early-stage setting. Patients with ALK-positive tumors of at least 4 cm or lymph node positivity benefited from therapy in the study What was the study? 📈Phase III ALINA trial demonstrated that adjuvant alectinib reduced risk for lung cancer recurrence by 76% vs. chemotherapy after surgical resection Congratulations to the patients and investigators! 🙌🏻 #precisionmedicine #NSCLCsm

🔥 Presidential Highlight from ESMO 2024! Dr Sheela Rao and Prof Dr Eric Van Cutsem present key findings from a pivotal study on metastatic anal cancer, exploring the addition of immunotherapy to standard chemotherapy: - PFS Improvement: The combination therapy showed a significant increase in PFS. - OS Trend: Early data indicate a possible six-month OS benefit. - Safety: The combination was well tolerated, with manageable immune-related side effects. Discover these updates.👇 For all ESMO 2024 videos, find the link in the comments! #MediMix #ESMO2024 #GICancer #Oncology #AnalCancer #ClinicalTrials #CancerResearch 

Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives 🔬 #ClinicalOncology #Oncology #Cancer

#Prostatecancer (PC) is the most common non-skin cancer in men in the US, and the 4th most common tumor diagnosed worldwide. #QPS experts are ready to manage your next PC #clinicaltrial. Download the Case Study today: https://shorturl.at/t5Cio or email us [email protected] #oncology

US FDA #AcceleratedApproval for the First Approved #Engineered #CellTherapy for a Solid Tumor. Approved for advanced MAGE-A4+ #synovial #sarcoma in adults with certain HLA types who have received prior chemotherapy TCR-T are T cells #engineered ex vivo to express tumor-antigen specific T cell receptors (TCRs) that recognise HLA-presented proteins (HLA restriction of TCRs) that may be derived from any cellular compartment unlikely from #CARs that recognise natively folded proteins at the cell surface. This difference has significant implications first of all the ability of TCR-T to aggressively target tumor cells while minimise toxicity towards healthy tissue.

A systematic review (DOI: 10.1097/DCR.0000000000003263) highlights neoadjuvant immunotherapy's high efficacy for mismatch repair deficient colon cancer, with 98-100% achieving complete R0 resections. The studies show a generally favorable safety profile, paving the way for new treatment protocols in a subset of colon cancer. Further research is needed to fully establish long-term outcomes and safety. #Oncology #CancerTherapy #MedicalInnovation #ClinicalStudies

Are you up-to-date with the latest data on metastatic castration-resistant prostate cancer (mCRPC)? Review expert-led highlights from #ASCO24 on Medthority https://ow.ly/Q1v250SqPwn #Oncology #MedEd #ProstateCancer #OncologyResearch

At Panavance, we are developing our pipeline with misetionamide (GP-2250) which has shown significant anti-neoplastic activity in preclinical studies across a range of cancers including #pancreaticcancer and ovarian cancer. Learn more about the unique mechanism of action here: https://lnkd.in/e2g_RsyP       #pancsm #disruptingcancersenergy   #oncology  

Congratulations to Adaptimmune on receiving U.S. FDA accelerated approval for TECELRA® (afamitresgene autoleucel), the first engineered cell therapy for a solid tumor in the U.S.! This groundbreaking treatment targets adults with MAGE-A4+ synovial sarcoma who have received prior chemotherapy and meet specific HLA types. Based on the SPEARHEAD-1 trial, TECELRA® demonstrated a 43% overall response rate and a 4.5% complete response rate, with a median duration of response of 6 months. As the first new treatment option in over a decade, TECELRA® offers new hope to patients who have long awaited innovative therapies. In celebrating this achievement, Biocytogen also stands at the forefront of supporting cancer treatment development, offering cutting-edge humanized models and fully human antibodies. Contact us to explore how Biocytogen can take your cancer research to the next level! #CancerTreatment #BiotechInnovation #SynovialSarcoma #CellTherapy #FDAApproval #Biocytogen #CancerResearch